Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study

Xinran Ma, MSc, Ling Li, Lei Zhang, Xin Li, Xiaorui Fu, Xinhua Wang, PhD, Jingjing Wu, Xudong Zhang, Xiaoyan Feng, Zhiyuan Zhou, Yu Chang, Zhaoming Li, MD PhD, Ken H. Young, Mingzhi Zhang

Blood (2019) 134 (Supplement_1): 2873.

https://doi.org/10.1182/blood-2019-127912

Published: 2019

Journal Articles

Efficacy and Safety of Novel Targeted Drug' Apatinib in Relapse or Refractory Non-Hodgkin Lymphoma: An Open Label, Single-Armed, Exploratory Study

Ling Li, MSPH, Sa Xiao, Ken H. Young, MD PhD, Lei Zhang, MD, Xin Li, MD, Xiaorui Fu, MDPhD, Zhaoming Li, MDPhD, Zhenchang Sun, MDPhD, Xudong Zhang, MDPhD, Jiaqin Yan, MDPhD, Feifei Nan, MDPhD, Yu Chang, Mengyuan Shi, graduate student, Mingzhi Zhang

Blood (2017) 130 (Supplement 1): 1548.

https://doi.org/10.1182/blood.V130.Suppl_1.1548.1548

Published: 2017

Journal Articles

Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML

Hiroto Inaba, MD PhD, John C Panetta, PhD, Daelynn R Buelow, PhD, Raul C. Ribeiro, MD, John R. Eckardt, MD, Sharyn D Baker, PharmD, PhD

Blood (2016) 128 (22): 3937.

https://doi.org/10.1182/blood.V128.22.3937.3937

Published: 2016

Journal Articles

Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Elias Jabbour, Marina Konopleva, MD PhD, Miranda Lim, BSN, Sherry Pierce, BSN, BA, Susan O'Brien, MD, Bradley G. Somer, MD, Ana Tari, PhD, William Wierda, MD PhD, Srdan Verstovsek, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3801.

https://doi.org/10.1182/blood.V126.23.3801.3801

Published: 2015

Journal Articles

Feasibility and Outcome of Sequential Therapy in the Setting of HLA-Haploidentical Transplantation Utilizing Reduced-Intensity Conditioning, T-Cell-Replete Grafts and Post-Transplantation High-Dose Cyclophosphamide in the Treatment of High-Risk AML and MDS

Dusan Prevalsek, MD, Susanne Fritsch, MD, Max Hubmann, MD, Nicole Engel, MD, Anna-Katharina Zoellner, MD, Thomas Köhnke, MD, Veit Leonhard Bücklein, MD, Christoph Schulz, MD, Friederike Mumm, MD, Christina Theresa Rieger, MD, Georg Ledderose, MD, Hans-Joachim Stemmler, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Andreas Hausmann, MD, Johanna Tischer, MD

Blood (2015) 126 (23): 4318.

https://doi.org/10.1182/blood.V126.23.4318.4318

Published: 2015

Journal Articles

A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma

Jesse Keller, MD, Mark A Fiala, BS, CCRP, Jeevan Sekhar, Connie Ceriotti, Melissa Allen, Camille N. Abboud, MD, Keith E. Stockerl-Goldstein, MD, Tanya M Wildes, MD MSCI, Michael H. Tomasson, MD, Ravi Vij, MBBS, MD

Blood (2014) 124 (21): 4731.

https://doi.org/10.1182/blood.V124.21.4731.4731

Published: 2014

Journal Articles

Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial

Blood (2014) 124 (21): 6.

https://doi.org/10.1182/blood.V124.21.6.6

Published: 2014

Journal Articles

Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Young Rock Chung, MSc, Helen Won, MS, Julie Teruya-Feldstein, MD, Michael Berger, PhD, Talal T Khawaja, BS, Mario E Lacouture, MD, Ross L. Levine, MD, Omar Abdel-Wahab, MD, Martin S Tallman, MD

Blood (2013) 122 (21): 2876.

https://doi.org/10.1182/blood.V122.21.2876.2876

Published: 2013

Journal Articles

Sequential Therapy Combining Clofarabine and HLA-Haploidentical Hematopoietic Stem Cell Transplantation In The Treatment Of Refractory and Advanced Lymphoma: Feasibility, Toxicity and Early Outcome

Anna-Katharina Zoellner, Susanne Fritsch, MD, Dusan Prevalsek, MD, Nicole Engel, MD, Roland Reibke, MD, Christina T Rieger, MD, PhD, Georg Ledderose, MD, Wolfgang Hiddemann, MD, Martin Dreyling, Andreas Hausmann, MD, Johanna Tischer, MD

Blood (2013) 122 (21): 4544.

https://doi.org/10.1182/blood.V122.21.4544.4544

Published: 2013

Journal Articles

Clofarabine Plus Low-Dose Cytarabine Induction Followed By Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine Consolidation In Acute Myeloid Leukemia Frontline Therapy For Older Patients

Aziz Nazha, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Xuelin Huang, Xuemei Wang, MS, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Alessandra Ferrajoli, MD, Marina Konopleva, MD, PhD, Gautam Borthakur, MD, Jan A. Burger, MD, PhD, Jennie Feliu, RN, Stefan H. Faderl, MD

Blood (2013) 122 (21): 3948.

https://doi.org/10.1182/blood.V122.21.3948.3948

Published: 2013

Journal Articles

Safety, Pharmacokinetics, and Efficacy Of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) In Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD, PhD, Elias Jabbour, MD, Marina Konopleva, MD, PhD, Susan O'Brien, MD, Alfonso Quintas-Cardama, MD, Bradley G. Somer, MD, Ana Tari, PhD, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2679.

https://doi.org/10.1182/blood.V122.21.2679.2679

Published: 2013

Journal Articles

Clofarabine Cytoreduction Followed by a Second Transplant Using Haploidentical Donors for Relapsed Acute Leukemia After First Allogeneic Hematopoietic Stem Cell Transplantation: Early Outcome, Infection and Toxicity.

Johanna Tischer, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Max Hubmann, MD, Veit Bücklein, Anna K Zöllner, MD, Christoph Schulz, MD, Roland Reibke, MD, Nicole Engel, MD, Christina T Rieger, MD, PhD, Christoph Schmid, MD, PhD, Georg Ledderose, MD, Wolfgang Hiddemann, MD, PhD, Andreas Hausmann, MD

Blood (2012) 120 (21): 3071.

https://doi.org/10.1182/blood.V120.21.3071.3071

Published: 2012

Journal Articles

Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory AML – Interim Results of the Bridge Trial

Jan Moritz Middeke, MD, Stefani Parmentier, MD, Nael Alakel, MD, Markus Schaich, MD, Christian Thiede, Uwe Platzbecker, MD, Christoph Röllig, Mathias Hänel, MD, Gernot Stuhler, MD, Anke Morgner, MD, Uta Eulenstein, Gerhard Ehninger, Martin Bornhäuser, MD, Johannes Schetelig, MD

Blood (2012) 120 (21): 2017.

https://doi.org/10.1182/blood.V120.21.2017.2017

Published: 2012

Journal Articles

Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML)

Michael S Mathisen, PharmD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Naveen Pemmaraju, M.D., Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Susan O'Brien, M.D., Alfonso Quintas-Cardama, MD, Hady Ghanem, MD, Naval G. Daver, MD, Sherry A. Pierce, RN, BS, Cynthia Lira, RN, Stefan Faderl, MD, Elias Jabbour, MD

Blood (2012) 120 (21): 3610.

https://doi.org/10.1182/blood.V120.21.3610.3610

Published: 2012

Journal Articles

A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes

Rajiv Agarwal, BA, Frederick L Locke, MD, Rangesh Kunnavakkam, MS, Koen van Besien, MD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Lucy Godley, MD, PhD, Hongtao Liu, MD, PhD, Michelle M. Le Beau, PhD, Sandeep Gurbuxani, MBBS, PhD, Michael J Thirman, MD, Dorothy A. Sipkins, M.D., Ph.D., Carol White, APN, Andrew Artz, MD, MS, Wendy Stock, MD

Blood (2011) 118 (21): 496.

https://doi.org/10.1182/blood.V118.21.496.496

Published: 2011

Journal Articles

Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS),

Jorge E. Cortes, Guillermo Garcia-Manero, Farhad Ravandi, MBBS, Michael Andreef, MD, PhD, Gautam Borthakur, Elias Jabbour, Marina Konopleva, M.D., Ph.D., Susan o'Brien, Alfonso Quintas-Cardama, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Hagop M. Kantarjian

Blood (2011) 118 (21): 3639.

https://doi.org/10.1182/blood.V118.21.3639.3639

Published: 2011

Journal Articles

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Peter M. Voorhees, MD, Cristina Gasparetto, MD, Keren Osman, MD, Kristy L. Richards, PhD, MD, Madlyn Ferraro, RN, OCN, CCRC, Reynaldo Garcia, RN, Jennifer MacLean, RN, OCN, Diane Winans, CCRP, Dominic Moore, PhD, John Strader, PA-C, Robert Z. Orlowski, MD, PhD, David Duane Hurd, MD

Blood (2011) 118 (21): 3985.

https://doi.org/10.1182/blood.V118.21.3985.3985

Published: 2011

Journal Articles

Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL)

David J. Straus, MD, Madeleine Duvic, MD, Steven M. Horwitz, MD, Kenneth B. Hymes, MD, Andre Goy, MD, Francisco J. Hernandez-Ilizaliturri, MD, Tatyana Feldman, MD, Brett Wegner, Patricia Myskowski, MD

Blood (2011) 118 (21): 882.

https://doi.org/10.1182/blood.V118.21.882.882

Published: 2011

Journal Articles

Escalation Trial of Clofarabine Followed by Escalating Dose of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute Leukemias,

Amer M. Zeidan, MD, Hetty E Carraway, MD, MBA, Hyun Don Yun, MD, Jacqueline M Greer, RN, Judith E. Karp, MD

Blood (2011) 118 (21): 3615.

https://doi.org/10.1182/blood.V118.21.3615.3615

Published: 2011

Journal Articles

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

Blood (2011) 118 (15): 4258–4264.

https://doi.org/10.1182/blood-2011-06-358010

Published: 2011

Includes: Supplemental data

NARROW

Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study

Efficacy and Safety of Novel Targeted Drug' Apatinib in Relapse or Refractory Non-Hodgkin Lymphoma: An Open Label, Single-Armed, Exploratory Study

Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML

Feasibility and Outcome of Sequential Therapy in the Setting of HLA-Haploidentical Transplantation Utilizing Reduced-Intensity Conditioning, T-Cell-Replete Grafts and Post-Transplantation High-Dose Cyclophosphamide in the Treatment of High-Risk AML and MDS

A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma

Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial

Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia

Sequential Therapy Combining Clofarabine and HLA-Haploidentical Hematopoietic Stem Cell Transplantation In The Treatment Of Refractory and Advanced Lymphoma: Feasibility, Toxicity and Early Outcome

Clofarabine Plus Low-Dose Cytarabine Induction Followed By Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine Consolidation In Acute Myeloid Leukemia Frontline Therapy For Older Patients

Clofarabine Cytoreduction Followed by a Second Transplant Using Haploidentical Donors for Relapsed Acute Leukemia After First Allogeneic Hematopoietic Stem Cell Transplantation: Early Outcome, Infection and Toxicity.

Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory AML – Interim Results of the Bridge Trial

Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML)

A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes

Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS),

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL)

Escalation Trial of Clofarabine Followed by Escalating Dose of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute Leukemias,

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only